Vozoris Nicholas T, Wang Xuesong, Austin Peter C, Lee Douglas S, Stephenson Anne L, O'Donnell Denis E, Gill Sudeep S, Rochon Paula A
Division of Respirology, Department of Medicine, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
Eur J Clin Pharmacol. 2017 Oct;73(10):1287-1295. doi: 10.1007/s00228-017-2278-3. Epub 2017 Jun 29.
We evaluated whether incident opioid drug use was associated with adverse cardiac events among older adults with chronic obstructive pulmonary disease (COPD).
This was an exploratory, retrospective cohort study using health administrative data from Ontario, Canada, from 2008 to 2013. Using a validated algorithm, we identified adults aged 66 years and older with non-palliative COPD. Hazard ratios (HR) were estimated for adverse cardiac events within 30 days of incident opioid receipt compared to controls using inverse probability of treatment weighting using the propensity score.
There were 134,408 community-dwelling individuals and 14,685 long-term care residents with COPD identified, 67.0 and 60.6% of whom received an incident opioid. Incident use of any opioid was associated with significantly decreased rates of emergency room (ER) visits and hospitalizations for congestive heart failure (CHF) among community-dwelling older adults (HR 0.84; 95% CI 0.73-0.97), but significantly increased rates of ischemic heart disease (IHD)-related mortality among long-term care residents (HR 2.15; 95% CI 1.50-3.09). In the community-dwelling group, users of more potent opioid-only agents without aspirin or acetaminophen combined had significantly increased rates of ER visits and hospitalizations for IHD (HR 1.38; 95% CI 1.08-1.77) and IHD-related mortality (HR 1.83; 95% CI 1.32-2.53).
New opioid use was associated with elevated rates of IHD-related morbidity and mortality among older adults with COPD. Adverse cardiac events may need to be considered when administering new opioids to older adults with COPD, but further studies are required to establish if the observed associations are causal or related to residual confounding.
我们评估了新发阿片类药物使用与慢性阻塞性肺疾病(COPD)老年患者不良心脏事件之间是否存在关联。
这是一项探索性的回顾性队列研究,使用了2008年至2013年加拿大安大略省的卫生行政数据。我们使用经过验证的算法,确定了66岁及以上患有非姑息性COPD的成年人。与对照组相比,使用倾向评分的逆概率治疗加权法,估计了首次接受阿片类药物后30天内不良心脏事件的风险比(HR)。
共识别出134408名社区居住的个体和14685名患有COPD的长期护理居民,其中分别有67.0%和60.6%的人首次接受了阿片类药物。在社区居住的老年人中,任何阿片类药物的首次使用与充血性心力衰竭(CHF)的急诊室(ER)就诊率和住院率显著降低相关(HR 0.84;95% CI 0.73 - 0.97),但在长期护理居民中,缺血性心脏病(IHD)相关死亡率显著增加(HR 2.15;95% CI 1.50 - 3.09)。在社区居住组中,仅使用更强效阿片类药物且未联合使用阿司匹林或对乙酰氨基酚的使用者,IHD的急诊室就诊率和住院率显著增加(HR 1.38;95% CI 1.08 - 1.77)以及IHD相关死亡率显著增加(HR 1.83;95% CI 1.32 - 2.53)。
新发阿片类药物使用与COPD老年患者IHD相关的发病率和死亡率升高有关。在给患有COPD的老年人使用新的阿片类药物时,可能需要考虑不良心脏事件,但需要进一步研究以确定观察到的关联是因果关系还是与残余混杂因素有关。